<i>BRCA</i> Mutation Frequency and Patterns of Treatment Response in <i>BRCA</i> Mutation–Positive Women With Ovarian Cancer: A Report From the Australian Ovarian Cancer Study GroupKathryn Alsop, Gillian Mitchell, Sián Fereday et al.|Journal of Clinical Oncology|2012Cited by 1.2k
Synthetic lethality between <i>CCNE1</i> amplification and loss of <i>BRCA1</i>Dariush Etemadmoghadam, David D.L. Bowtell, Barbara A. Weir et al.|Proceedings of the National Academy of Sciences|2013Cited by 227
Deregulation of MYCN, LIN28B and LET7 in a Molecular Subtype of Aggressive High-Grade Serous Ovarian CancersÅslaug Helland, David D.L. Bowtell, Michael S. Anglesio et al.|PLoS ONE|2011Cited by 219
CUP-AI-Dx: A tool for inferring cancer tissue of origin and molecular subtype using RNA gene-expression data and artificial intelligenceYue Zhao, Joshy George, Stephen B. Fox et al.|EBioMedicine|2020Cited by 134
Nonequivalent Gene Expression and Copy Number Alterations in High-Grade Serous Ovarian Cancers with <i>BRCA1</i> and <i>BRCA2</i> MutationsJoshy George, David D.L. Bowtell, Kathryn Alsop et al.|Clinical Cancer Research|2013Cited by 90